Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Back

Showing results (31-40 of 147) with videos related to

Pageof 15
Sort By:
Journal of the International AIDS Society|November 14, 2014
Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approachLaura Dickinson, Alan Winston, Marta Boffito, et al.
Arthritis and Rheumatism|February 5, 2005
Drug efflux transporters in rheumatoid arthritis: comment on the article by KremerSamantha L Hider, Patrick Hoggard, Saye Khoo, et al.
Clinical Pharmacokinetics|September 24, 2014
Use of in vitro to in vivo extrapolation to predict the optimal strategy for patients switching from efavirenz to maraviroc or nevirapineAlessandro Schipani, David Back, Andrew Owen, et al.
AIDS (London, England)|September 16, 2015
Increasing use of 'party drugs' in people living with HIV on antiretrovirals: a concern for patient safetyMargherita Bracchi, David Stuart, Richard Castles, et al.
The Journal of Antimicrobial Chemotherapy|December 30, 2015
Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approachLaura Dickinson, Alan Winston, Marta Boffito, et al.
Acta Pharmacologica Sinica|January 6, 2010
Effect of prototypical inducers on ligand activated nuclear receptor regulated drug disposition genes in rodent hepatic and intestinal cellsPhilip Martin, Robert Riley, Paul Thompson, et al.
Clinical Pharmacokinetics|September 8, 2016
Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on CytochromesCatia Marzolini, Rajith Rajoli, Manuel Battegay, et al.
Pharmacogenetics and Genomics|May 20, 2016
Pregnancy affects nevirapine pharmacokinetics: evidence from a CYP2B6 genotype-guided observational studyAdeniyi Olagunju, Oluseye Bolaji, Megan Neary, et al.
Expert Review of Gastroenterology & Hepatology|October 11, 2016
Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infectionElisabetta Degasperi, Flavio Caprioli, Omar El Sherif, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 7, 2003
The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitroBecky Chandler, Lisa Almond, Jennifer Ford, et al.
Pageof 15

Showing results (31-40 of 147) with videos related to

Sort By:
Pageof 15
Journal of the International AIDS Society|November 14, 2014
Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approachLaura Dickinson, Alan Winston, Marta Boffito, et al.
Arthritis and Rheumatism|February 5, 2005
Drug efflux transporters in rheumatoid arthritis: comment on the article by KremerSamantha L Hider, Patrick Hoggard, Saye Khoo, et al.
Clinical Pharmacokinetics|September 24, 2014
Use of in vitro to in vivo extrapolation to predict the optimal strategy for patients switching from efavirenz to maraviroc or nevirapineAlessandro Schipani, David Back, Andrew Owen, et al.
AIDS (London, England)|September 16, 2015
Increasing use of 'party drugs' in people living with HIV on antiretrovirals: a concern for patient safetyMargherita Bracchi, David Stuart, Richard Castles, et al.
The Journal of Antimicrobial Chemotherapy|December 30, 2015
Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approachLaura Dickinson, Alan Winston, Marta Boffito, et al.
Acta Pharmacologica Sinica|January 6, 2010
Effect of prototypical inducers on ligand activated nuclear receptor regulated drug disposition genes in rodent hepatic and intestinal cellsPhilip Martin, Robert Riley, Paul Thompson, et al.
Clinical Pharmacokinetics|September 8, 2016
Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on CytochromesCatia Marzolini, Rajith Rajoli, Manuel Battegay, et al.
Pharmacogenetics and Genomics|May 20, 2016
Pregnancy affects nevirapine pharmacokinetics: evidence from a CYP2B6 genotype-guided observational studyAdeniyi Olagunju, Oluseye Bolaji, Megan Neary, et al.
Expert Review of Gastroenterology & Hepatology|October 11, 2016
Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infectionElisabetta Degasperi, Flavio Caprioli, Omar El Sherif, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 7, 2003
The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitroBecky Chandler, Lisa Almond, Jennifer Ford, et al.
Pageof 15